- The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
-
Taki S, Tamai H, Ida Y, Shingaki N, Kawashima , Shimizu R, Moribata K, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2404722
- Gut Liver.
- 2018 Jan;12(1):86-93.
- doi: 10.5009/gnl17048
BACKGROUND/AIMS: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed... -
- CITED
-
- Close
- SHARE
-
- Close
- The impact of donor-specific alloantibodies on chronic antibodymediated rejection after pediatric living donor liver transplantation
-
Shimizu S, Sakamoto S, Fukuda A, Yanagi Y, Uchida H, Mimori K, Nakao T, Yamada M, Yoshioka T, Kasahara M
- KMID: 2521267
- Korean J Transplant.
- 2021 Oct;35(Supple 1):S42.
- doi: 10.4285/ATW2021.OR-1094
Background: The development of anti-human leukocyte antigen donor-specific alloantibodies (DSA) after living donor liver transplantation (LDLT) can lead to chronic antibody-mediated rejection (cAMR). This study aimed to analyze the detail... -
- CITED
-
- Close
- SHARE
-
- Close
- Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
-
Tamai H, Ida Y, Kawashima , Shingaki N, Shimizu R, Moribata K, Nasu T, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2412236
- Gut Liver.
- 2017 Jul;11(4):551-558.
- doi: 10.5009/gnl16525
BACKGROUND/AIMS: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such... -
- CITED
-
- Close
- SHARE
-
- Close
